Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 18/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4643554 | 0.80 | KDM4E (0.48) | SLC6A9NPC1RAB9APOLBTHRB | |
| SCHEMBL4644071 | 0.80 | KDM4E (0.48) | SLC6A9NPC1RAB9APOLBTHRB | |
| SCHEMBL3043124 | 0.80 | KDM4E (0.48) | SLC6A9NPC1RAB9APOLBTHRB | |
| SCHEMBL3042565 | 0.78 | SLC6A9 (0.58) | SLC6A9 | |
| SCHEMBL3049316 | 0.76 | NPC1 (0.48) | SLC6A9NPC1RAB9APOLBTHRB | |
| SCHEMBL3061380 | 0.75 | NPC1 (0.47) | SLC6A9NPC1RAB9APOLBTHRB | |
| SCHEMBL4721249 | 0.75 | SLC6A9 (0.56) | SLC6A9NPC1RAB9A | |
| SCHEMBL3052683 | 0.75 | PSMB11 (0.38) | SLC6A9 | |
| SCHEMBL13137865 | 0.74 | SLC6A9 (0.72) | SLC6A9 | |
| SCHEMBL3053101 | 0.74 | SLC6A9 (0.72) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | SLC6A9 18/4885NPC1 115/4885RAB9A 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.